DA32 Life Science Tech Ac... (DALS)
10.30
-0.02 (-0.19%)
At close: Jul 28, 2023, 7:51 PM
Company Description
DA32 Life Science Tech Acquisition Corp. does not have significant operations.
It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses.
The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors.
DA32 Life Science Tech Acquisition Corp. was incorporated in 2021 and is based in New York, New York.
DA32 Life Science Tech Acquisition Corp.
| Country | United States |
| IPO Date | Jul 28, 2021 |
| Industry | Shell Companies |
| Sector | Financial Services |
| Employees | n/a |
| CEO | Dr. Steven Kafka Ph.D. |
Contact Details
Address: 345 Park Avenue South New York, New York United States | |
| Website | n/a |
Stock Details
| Ticker Symbol | DALS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001863294 |
| CUSIP Number | 23312M106 |
| ISIN Number | US23312M1062 |
| Employer ID | 86-3352988 |
| SIC Code | 6770 |
Key Executives
| Name | Position |
|---|---|
| Dr. Steven Kafka Ph.D. | Chief Executive Officer & Director |
| Christopher E. Wolfe | Chief Financial Officer & Sec. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 07, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 11, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 10, 2023 | 4 | Filing |
| Aug 10, 2023 | 4 | Filing |
| Aug 08, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 08, 2023 | 15-12G | Filing |
| Aug 04, 2023 | SC 13D/A | [Amend] Filing |
| Aug 02, 2023 | SC 13D/A | [Amend] Filing |
| Aug 01, 2023 | 4 | Filing |
| Aug 01, 2023 | SC 13D/A | [Amend] Filing |